Ophelia is a digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), committed to making evidence-based treatment universally accessible. Its mission is to remove barriers for the 80% of Americans with OUD who are unable to access care and the 50,000+ MAT-licensed clinicians who are unable to treat patients due to a lack of infrastructure, training, and support.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/16/21 | $50,000,000 | Series B |
640 Oxford Ventures Elliot Cohen Good Friends Interplay Ventures Menlo Ventures Refactor Capital Tiger Global Management  | undisclosed |
